Tosk, Inc.

Tosk, Inc. is a biopharmaceutical company that focuses on discovering and developing new drugs to address the adverse effects of cancer therapy and block the activity of cancer genes. With the slogan "New Drugs to Prevent Cancer Therapy Side Effects and Block the Activity of Cancer Genes," Tosk has gained attention for its innovative approach to tackling the challenges of cancer treatment. The company, founded in 1998 and headquartered in the United States, has made significant strides in its drug development efforts. One of Tosk's most promising drugs, TK-90, has shown promise in Phase 2 studies for head and neck cancer patients undergoing high-dose chemotherapy. Additionally, the company has two other drugs in development focused on preventing side effects of cancer therapy, as well as a drug targeting the KRAS gene activity, which is implicated in up to 30% of all cancers. Notably, Tosk recently secured a $100.00K debt financing investment on 15 September 2022, indicating ongoing support and interest in the company's endeavors. The identity of the investors for this particular investment round has not been disclosed. Tosk's commitment to addressing unmet medical needs in cancer treatment, coupled with its focus on innovative drug development, positions the company as a compelling player in the biopharma and biotechnology industries. As Tosk continues to progress its drug candidates through clinical development, it holds the potential to make a significant impact on improving cancer treatment outcomes.